Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levosimendan for coronary heart disease with heart failure and mid-range ejection fraction
ChiCTR1900024236Phase 4Recruiting
- Sponsor
- Shandong Provincial Hospital Affiliated to Shandong First Medical University
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of levosimendan in heart failure with mid-range ejection fraction (HFmrEF) and coronary arteriosclerosis (2 arms), sponsored by Shandong Provincial Hospital Affiliated to Shandong First Medical University. Primary endpoints: High-sensitivity troponin T, N-terminal pro-brain natriuretic peptide and 4 more. Started Jul 2019; status: recruiting.
02
Drugs
levosimendan
03
Conditions
heart failure with mid-range ejection fraction (HFmrEF)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR1900024236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900024236.